Cellectar Biosciencesincis A Late Stage Clinical Biopharmaceutical Company Focused On Developing Targeted Cancer Therapies Using Its Proprietary Phospholipid Drug Conjugatea Cpdcplatformthe Company Aims To Improve Treatment Efficacy And Safety By Minimizing Off Target Effectsaddressing Significant Unmet Medical Needs In Oncology Cellectar S Pdc Technology Allows For Systematic Screening Of Drug Candidatesoptimizing Delivery To Hard To Treat Cancers While Reducing Damage To Healthy Tissuesthe Company Has A Robust Product Pipelineincluding Iopofosine I 131Which Is In Phase 2B Trials For Relapsed Refractory Multiple Myeloma And Cns Lymphomaand Clr 121225An Actinium 225 Based Therapy Targeting Solid Tumorscellectar Also Engages In Research Collaborations To Expand Its Pipeline And Accelerate Development With A Team Of Industry Veteranscellectar Is Exploring Strategic Alternatives To Enhance Growthfocusing On Markets With Limited Competition And Scalable Opportunitiesthe Company Is Dedicated To Developing Therapies For Oncology Patients With High Unmet Needsparticularly Those Eligible For Accelerated Regulatory Pathways
United States
